2009

 

Numerous factors and incorrect measurements can lead to misinterpretations. Be critical when dealing with hormone

Bidlingmaier M.

MMW Fortschr Med. 2009 Oct 15;151(42):36. German. No abstract available.

 

Measurement of human growth hormone by immunoassays: Current status, unsolved problems and clinical consequences.

Bidlingmaier M, Freda PU.

Growth Horm IGF Res. 2009 Oct 7.

 

Short Term Exposure to Low-Carbohydrate / High Fat Diets Induces Low Bone Mineral Density and Reduces Bone Formation in Rats.

Bielohuby M, Matsuura M, Herbach N, Kienzle E, Slawik M, Hoeflich A, Bidlingmaier M.

J Bone Miner Res. 2009 Aug 4

 

Influence of long-term growth hormone replacement on leptin and ghrelin in GH deficiency before and after glucose load.

Roemmler J, Kuenkler M, Otto B, Arafat AM, Bidlingmaier M, Schopohl J.

Regul Pept. 2009 Jul 19.

 

The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry.

Schirpenbach C, Segmiller F, Diederich S, Hahner S, Lorenz R, Rump LC, Seufert J, Quinkler M, Bidlingmaier M, Beuschlein F, Endres S, Reincke M.

Dtsch Arztebl Int. 2009 May;106(18):305-11. Epub 2009 May 1.

 

Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice.

Bielohuby M, Roemmler J, Manolopoulou J, Johnsen I, Sawitzky M, Schopohl J, Reincke M, Wolf E, Hoeflich A, Bidlingmaier M.

Exp Biol Med (Maywood). 2009 Aug;234(8):1002-9. Epub 2009 Jun 2.

 

Saliva as a medium for aldosterone measurement in repeated sampling studies.

Manolopoulou J, Mulatero P, Maser-Gluth C, Rossignol P, Spyroglou A, Vakrilova Y, Petersenn S, Zwermann O, Plouin PF, Reincke M, Bidlingmaier M.

Steroids. 2009 Oct;74(10-11):853-8. Epub 2009 May 27.

 

Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study.

Buchfelder M, Weigel D, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Bidlingmaier M, Strasburger CJ; Investigators of German Pegvisomant Observational Study.

Eur J Endocrinol. 2009 Jul;161(1):27-35. Epub 2009 May 1.

 

Successful use of weekly pegvisomant administration in patients with acromegaly.

Higham CE, Thomas JD, Bidlingmaier M, Drake WM, Trainer PJ.

Eur J Endocrinol. 2009 Jul;161(1):21-5. Epub 2009 May 1.

 

High prevalence of reduced fecundity in men with congenital adrenal hyperplasia.

Reisch N, Flade L, Scherr M, Rottenkolber M, Pedrosa Gil F, Bidlingmaier M, Wolff H, Schwarz HP, Quinkler M, Beuschlein F, Reincke M.

 

Decreased p44/42 MAPK phosphorylation in gender- or hormonerelated but not during age-related adrenal gland growth in mice

Bielohuby M., Sawitzky M., Johnsen I., Wittenburg D., Beuschlein F., Wolf E. and Hoeflich A.

(Endocrinology; 150(3):1269-77, 3/2009)

 

Mechanisms of adrenal gland growth - signal integration by ERK1/2

Hoeflich A. and Bielohuby M.

(J Mol Endocrinol, 42(3):191-203. 3/2009)

 

Short term regulation of aldosterone secretion after stimulation and suppression experiments in mice.

Spyroglou A, Manolopoulou J, Wagner S, Bidlingmaier M, Reincke M, Beuschlein F.

J Mol Endocrinol. 2009 May;42(5):407-13. Epub 2009 Feb 12.

 

Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry.

Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Endres S, Quinkler M; Participants of the German Conn's Registry.

J Clin Endocrinol Metab. 2009 Apr;94(4):1125-30. Epub 2009 Feb 3.

 

Pitfalls of insulin-like growth factor I assays.

Bidlingmaier M.

Horm Res. 2009 Jan;71 Suppl 1:30-3. Epub 2009 Jan 21. Review.

 

High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports.

Bidlingmaier M, Suhr J, Ernst A, Wu Z, Keller A, Strasburger CJ, Bergmann A.

Clin Chem. 2009 Mar;55(3):445-53. Epub 2009 Jan 23.

 

Screening for membrane hormone receptor expression in primary aldosteronism.

Zwermann O, Suttmann Y, Bidlingmaier M, Beuschlein F, Reincke M.

Eur J Endocrinol. 2009 Mar;160(3):443-51. Epub 2009 Jan 8.

 

Risk factors associated with a low glomerular filtration rate in primary aldosteronism.

Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Meisinger C, Holle R, Endres S; Participants of German Conn's Registry.

J Clin Endocrinol Metab. 2009 Mar;94(3):869-75. Epub 2008 Dec 30.

 

The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment.

Roemmler J, Steffin B, Gutt B, Sievers C, Bidlingmaier M, Schopohl J.

Growth Horm IGF Res. 2009 Jun;19(3):245-51. Epub 2008 Dec 23.

 

Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency.

Peter F, Savoy C, Ji HJ, Juhasz M, Bidlingmaier M, Saenger P.

Eur J Endocrinol. 2009 Mar;160(3):349-55. Epub 2008 Dec 12.

 

Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD).

Berg CA, Pokrajac A, Bidlingmaier M, Strasburger CJ, Shalet SM, Trainer PJ.

Clin Endocrinol (Oxf). 2009 Mar;70(3):439-45. Epub 2008 Dec 3.

 

Low-carbohydrate high-fat diets: regulation of energy balance and body weight regain in rats.

Caton SJ, Yinglong B, Burget L, Spangler LJ, Tschöp MH, Bidlingmaier M.

Obesity (Silver Spring). 2009 Feb;17(2):283-9. Epub 2008 Nov 27.